title: Life threatening liver disease during treatment with monoclonal antibodies.
authors.affiliation: Medizinische Klinik und Poliklinik II, Universität Leipzig, 04103 Leipzig, Germany.
authors.forename: Thorsten
authors.initials: T
authors.lastname: Kaiser
authors.forename: Joachim
authors.initials: J
authors.lastname: Moessner
authors.forename: Keyur
authors.initials: K
authors.lastname: Patel
authors.forename: John G
authors.initials: JG
authors.lastname: McHutchison
authors.forename: Hans L
authors.initials: HL
authors.lastname: Tillmann
mesh_terms: D000068879:Adalimumab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001778:Blood Coagulation Disorders / Q000139:chemically induced; D056487:Chemical and Drug Induced Liver Injury, Chronic / Q000209:etiology*; D016638:Critical Illness / Q000628:therapy*; D019694:Hepatitis B, Chronic / Q000209:etiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007565:Jaundice / Q000139:chemically induced; D008297:Male; D011565:Psoriasis / Q000188:drug therapy*; D012008:Recurrence
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000068879:Adalimumab; C472181:efalizumab